bullish
Lotus Pharmaceutical (1795 TT) Growth Story for Blood Cancer Drugs
Lotus’ profits will remain upbeat thanks to stable market share for its main product Suboxone and its anti-obesity drug business in South Korea....
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 1-minute read)
Discussions
(Paid Plans Only)
x